Clinical and histological outcome after hepatitis B e antigen to antibody seroconversion in children with chronic hepatitis B

被引:42
作者
Ruiz-Moreno, M
Otero, M
Millán, A
Castillo, I
Cabrerizo, M
Jiménez, FJ
Oliva, H
Cajal, SRY
Carreño, V
机构
[1] Fdn Jimenez Diaz, Dept Hepatol, E-28040 Madrid, Spain
[2] Fdn Jimenez Diaz, Dept Paediat, E-28040 Madrid, Spain
[3] Fdn Jimenez Diaz, Dept Res, E-28040 Madrid, Spain
[4] Fdn Jimenez Diaz, Dept Pathol, E-28040 Madrid, Spain
[5] Clin Puerta Hierro, Dept Pathol, Madrid, Spain
关键词
D O I
10.1002/hep.510290230
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Data regarding the outcome of children with chronic hepatitis B after seroconversion are scarce. We describe the long-term evolution of these patients. One hundred and three children with antibody against hepatitis B e antigen and normal alanine aminotransferase (ALT) levels were followed for 0.6 to 12.5 years (mean, 6.3 years). Paired liver biopsies (before and after seroconversion) were available in 83 cases. Final biopsies were obtained 0.5 to 12.5 years (mean, 4.5 years) after seroconversion, ALT levels remained normal in most of the children (79%) throughout the follow-up, All children, except five who lost hepatitis B surface antigen, had serum viral DNA detected by polymerase chain reaction. When comparing baseline and final liver biopsies, a significant improvement (P < .001) was found in the histological activity index and in the necrosis, cytolysis, inflammation, and fibrosis scores. The histological diagosis improvement in the final biopsy was significantly related (P < .001) to the time from seroconversion to the biopsy performance, All children had viral DNA on their final liver biopsy. In summary, seroconversion and ALT normalization are quite stable findings in children, and no differences in the long-term outcome between treated and untreated children were found. In light of the histological outcome, it seems unnecessary to perform a follow-up liver biopsy in these cases.
引用
收藏
页码:572 / 575
页数:4
相关论文
共 24 条
[1]   AN ASSAY FOR THE DETECTION OF THE DNA GENOME OF HEPATITIS-B VIRUS IN SERUM [J].
BERNINGER, M ;
HAMMER, M ;
HOYER, B ;
GERIN, JL .
JOURNAL OF MEDICAL VIROLOGY, 1982, 9 (01) :57-68
[2]   LONG-TERM FOLLOW-UP OF HEPATITIS-B CHRONIC CARRIERS WHO RESPONDED TO INTERFERON THERAPY [J].
CARRENO, V ;
CASTILLO, I ;
MOLINA, J ;
PORRES, JC ;
BARTOLOME, J .
JOURNAL OF HEPATOLOGY, 1992, 15 (1-2) :102-106
[3]  
CHANG MH, 1995, HEPATOLOGY, V22, P1387, DOI 10.1002/hep.1840220508
[4]  
DESMET VJ, 1994, HEPATOLOGY, V19, P1513, DOI 10.1002/hep.1840190629
[5]   CLINICAL, VIROLOGICAL AND HISTOLOGIC OUTCOME FOLLOWING SEROCONVERSION FROM HEBEAG TO ANTI-HBE IN CHRONIC HEPATITIS TYPE-B [J].
FATTOVICH, G ;
RUGGE, M ;
BROLLO, L ;
PONTISSO, P ;
NOVENTA, F ;
GUIDO, M ;
ALBERTI, A ;
REALDI, G .
HEPATOLOGY, 1986, 6 (02) :167-172
[6]   PERSISTENCE OF HEPATITIS-B VIRUS-DNA IN THE LIVER AFTER LOSS OF HBSAG IN CHRONIC HEPATITIS-B [J].
FONG, TL ;
DIBISCEGLIE, AM ;
GERBER, MA ;
WAGGONER, JG ;
HOOFNAGLE, JH .
HEPATOLOGY, 1993, 18 (06) :1313-1318
[7]   RANDOMIZED, CONTROLLED TRIAL OF RECOMBINANT HUMAN ALPHA-INTERFERON IN PATIENTS WITH CHRONIC HEPATITIS-B [J].
HOOFNAGLE, JH ;
PETERS, M ;
MULLEN, KD ;
JONES, DB ;
RUSTGI, V ;
DIBISCEGLIE, A ;
HALLAHAN, C ;
PARK, Y ;
MESCHIEVITZ, C ;
JONES, EA .
GASTROENTEROLOGY, 1988, 95 (05) :1318-1325
[8]   CHRONIC TYPE-B HEPATITIS AND THE HEALTHY HBSAG CARRIER STATE [J].
HOOFNAGLE, JH ;
SHAFRITZ, DA ;
POPPER, H .
HEPATOLOGY, 1987, 7 (04) :758-763
[9]   REACTIVATION OF CHRONIC HEPATITIS B-VIRUS INFECTION BY CANCER-CHEMOTHERAPY [J].
HOOFNAGLE, JH ;
DUSHEIKO, GM ;
SCHAFER, DF ;
JONES, EA ;
MICETICH, KC ;
YOUNG, RC ;
COSTA, J .
ANNALS OF INTERNAL MEDICINE, 1982, 96 (04) :447-449
[10]   LONG-TERM REMISSION OF CHRONIC HEPATITIS-B AFTER ALPHA-INTERFERON THERAPY [J].
KORENMAN, J ;
BAKER, B ;
WAGGONER, J ;
EVERHART, JE ;
DIBISCEGLIE, AM ;
HOOFNAGLE, JH .
ANNALS OF INTERNAL MEDICINE, 1991, 114 (08) :629-634